CollPlant Biotechnologies Ltd. (CLGN)
| Previous Close | 5.50 |
| Open | 5.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.50 - 5.61 |
| 52 Week Range | 4.22 - 8.90 |
| Volume | |
| Avg. Volume | 6,574 |
| Market Cap | 64.202M |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
- PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates
- PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
